<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="case-report"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Med Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">J Med Case Rep</journal-id><journal-title-group><journal-title>Journal of Medical Case Reports</journal-title></journal-title-group><issn pub-type="epub">1752-1947</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4895981</article-id><article-id pub-id-type="publisher-id">938</article-id><article-id pub-id-type="doi">10.1186/s13256-016-0938-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject></subj-group></article-categories><title-group><article-title>Thrombotic microangiopathy as first manifestation of acute human immunodeficiency virus infection: a case report and review of the literature</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Sarmiento</surname><given-names>M.</given-names></name><address><email>mauriciosarmiento@hotmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Balcells</surname><given-names>M. E.</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Ramirez</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Departamento de Hematolog&#x000ed;a y Oncolog&#x000ed;a, Facultad de Medicina, Pontificia Universidad Cat&#x000f3;lica de Chile, Santiago, Regi&#x000f3;n Metropolitana Chile </aff><aff id="Aff2"><label/>Departamento de Enfermedades Infecciosas, Facultad de Medicina, Pontificia Universidad Cat&#x000f3;lica de Chile, Santiago, Regi&#x000f3;n Metropolitana Chile </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>10</volume><elocation-id>152</elocation-id><history><date date-type="received"><day>11</day><month>9</month><year>2015</year></date><date date-type="accepted"><day>6</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Sarmiento et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>We present the case of a patient with acute human immunodeficiency virus infection and a thrombotic microangiopathy as the first clinical manifestation, a presentation that has not, to the best of our knowledge, been previously reported.</p></sec><sec><title>Case presentation</title><p>A 35-year-old Bolivian man presented with epistaxis and thrombocytopenia. We found microangiopathic anemia, lymphopenia, elevated lactate dehydrogenase, progressive acute renal failure, negative direct antiglobulin test, and normal activity of ADAMTS13. An human immunodeficiency virus ELISA test was negative, with an human immunodeficiency virus viral load of 10,000,000 RNA copies/mL. Antiretroviral therapy and three sessions of therapeutic plasma exchange were able to control thrombotic microangiopathy.</p></sec><sec><title>Conclusions</title><p>Hematologic manifestations of human immunodeficiency virus infection are frequent. However, the debut of acute human immunodeficiency virus infection with thrombotic microangiopathy is a rare event. A high index of suspicion and early treatment is required.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Human immunodeficiency virus</kwd><kwd>Acute HIV infection</kwd><kwd>Thrombotic microangiopathy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>In the majority of cases, early human immunodeficiency virus (HIV) infection is asymptomatic [<xref ref-type="bibr" rid="CR1">1</xref>]. In those patients with symptoms a variety of clinical manifestations may be seen, including hematological alterations. Anemia and leukopenia can be found in up to 70 % of patients at some point during the course of this viral infection, while thrombocytopenia is usually mild and occurs at the beginning of the infection due to lower production and increased platelet destruction rate [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. Other coagulation disorders such as antiphospholipid syndrome-associated thrombosis and protein C and protein S deficiency can also occur, but infrequently. Thrombotic thrombocytopenic purpura (TTP) and thrombotic microangiopathy (TMA) have been occasionally described in patients with HIV in advanced stages of infection. However, the debut of acute HIV infection with TTP or TMA is rare [<xref ref-type="bibr" rid="CR4">4</xref>]. We present a case of a patient with acute HIV infection with a severe TMA and a complete response to therapeutic plasma exchange (TPE) and antiretroviral therapy (ART).</p></sec><sec id="Sec2"><title>Case presentation</title><p>A 35-year-old previously healthy Bolivian man presented with continuous epistaxis, fever, fatigue, and sore throat. He had a history of unprotected sexual activity during the previous month. A physical examination on admission revealed no major alterations, with the exception of ear, nose, and throat evaluation that showed an intense mucosal bleeding without any visible injury and only partial response to nasal packing. Laboratory tests showed lymphopenia, anemia, severe thrombocytopenia, acute renal failure, lactate dehydrogenase (LDH) twice over normal value, and hyperbilirubinemia that progressively worsened during the first week of hospitalization (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). A specific hematological study was conducted and schistocytes were found along with negative direct antiglobulin test (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). TTP was suspected and TPE was promptly initiated on the fourth day of admission; he reached normal platelet counts and renal function after three daily TPE procedures. His disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) level was normal at day 8 (118 %; normal value 20 to 100 %). Infectious diseases investigations showed a negative ELISA HIV test, but a plasma HIV viral load of &#x0003e;10 million/RNA copies per mL and slightly low CD4 cell count (398 cell/uL). We did not find any opportunistic infections or other viral infections. Acute HIV infection was diagnosed and ART was started with tenofovir, emtricitabine, and raltegravir. After a 13-day hospital stay, he was discharged in good condition without any further evidence of TMA. A 6-month follow-up showed he had good tolerance to antiretroviral treatment and he had normal blood counts and renal function (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Laboratory values at diagnosis and follow-up</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Day 1</th><th>Day 4</th><th>Day 8</th><th>Day 15</th><th>Day 90</th></tr></thead><tbody><tr><td>Hemoglobin gr/dL</td><td>11.4</td><td>9.4</td><td>11.9</td><td>10</td><td>11</td></tr><tr><td>Leucocytes &#x000d7;1000 cells/uL</td><td>5.6</td><td>3.8</td><td>6.2</td><td>5.2</td><td>5.4</td></tr><tr><td>Lymphocytes &#x000d7;1000 cells/uL</td><td>0.8</td><td>0.9</td><td>1.2</td><td>1.4</td><td>1.8</td></tr><tr><td>Platelets &#x000d7;1000 cells/uL</td><td>17</td><td>12</td><td>90</td><td>308</td><td>420</td></tr><tr><td>Creatinine mg/dL</td><td>1.2</td><td>1.6</td><td>0.8</td><td>0.8</td><td>0.9</td></tr><tr><td>Bilirubin mg/dL</td><td>1.33</td><td>1.9</td><td>1.2</td><td>0.8</td><td>0.7</td></tr><tr><td>Lactate dehydrogenase U/L</td><td>600</td><td>1800</td><td>457</td><td>413</td><td>300</td></tr><tr><td>Schistocytes %</td><td>3</td><td>4</td><td>1</td><td>0</td><td>0</td></tr><tr><td>Fibrinogen mg/dL</td><td>325</td><td>400</td><td/><td>218</td><td/></tr><tr><td>ADAMTS13 %</td><td/><td/><td>120</td><td/><td/></tr><tr><td>Haptoglobin mg/dL</td><td>25</td><td/><td>80</td><td>120</td><td/></tr></tbody></table><table-wrap-foot><p>Reference values: hemoglobin 12&#x02013;16 gr/dL, leucocytes 4.5&#x02013;11.0/uL, lymphocytes 1.2&#x02013;4.5 &#x000d7;10<sup>3</sup>/uL<italic>,</italic> platelets 150&#x02013;400 &#x000d7;10<sup>3</sup>/uL, creatinine 0.6&#x02013;1.1 mg/dL, bilirubin 0.6&#x02013;1.0 mg/dL, lactate dehydrogenase 180&#x02013;225 U/L, schistocytes &#x0003c;0.5 %, fibrinogen 200&#x02013;400 mg/dL, ADAMTS13 &#x0003e;20 %, haptoglobin 20&#x02013;200 mg/dL. <italic>ADAMTS13</italic> disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13</p></table-wrap-foot></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Peripheral blood smear with microangiopathic anemia (&#x000d7;100 optical microscopy). Scarce platelets and abundant schistocytes, acanthocytes and red cell destruction are evident</p></caption><graphic xlink:href="13256_2016_938_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Chronological schema of clinical and laboratory follow-up characteristics. <italic>Cr</italic> creatinine, <italic>Hb</italic> hemoglobin, <italic>LDH</italic> lactate dehydrogenase, <italic>PLT</italic> platelets, <italic>TPE</italic> therapeutic plasma exchange</p></caption><graphic xlink:href="13256_2016_938_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec3" sec-type="discussion"><title>Discussion</title><p>This case demonstrates the wide variation of clinical manifestations found in patients with early HIV infection. The most frequent hematological findings in this condition are changes to peripheral blood cells, although coagulation disorders may also occur. Furthermore, the coexistence of immunological-mediated thrombocytopenia with TTP has been reported in chronic HIV infection [<xref ref-type="bibr" rid="CR5">5</xref>].</p><p>Thrombotic manifestations such as serious thrombosis, TTP, and TMA usually occur in late stages of chronic HIV infection or in patients with poor adherence to ART [<xref ref-type="bibr" rid="CR6">6</xref>]. The classic form of TTP is caused by an acquired or hereditary malfunction/deficit of ADAMTS13, which fails to cleave the ultra-large multimers of the von-Willebrand factor (v-WF) and produces classic thrombotic microangiopathic anemia and multiorgan failure [<xref ref-type="bibr" rid="CR7">7</xref>]. On the other hand, TMA associated with drugs, neoplasia, or infections has the same features as classic TTP but other mechanisms lead to thrombosis without ADAMTS13 inhibition. In HIV infection, multiple alterations have been described that can induce either immune TTP triggered by dysfunctional ADAMTS13 or TMA generated by diverse conditions such as alterations to complement proteins, endothelial injury secondary to cytokines induced by the virus, or endothelial cell damage directly mediated by viral particles [<xref ref-type="bibr" rid="CR8">8</xref>]. Because of these multiple pathological pathways, treatment of patients with either TTP or TMA associated to HIV should be directed to rapidly control the viral load, reduce the virus-induced immunosuppression, and replace the defective ADAMTS13 and coagulation proteins by TPE.</p><p>Miller <italic>et al</italic>. showed that 12 % of patients diagnosed with TTP had concomitant HIV infection, and they were more often found to be at advanced stages of the disease with profound immunosuppression. In this situation, there was a clear therapeutic benefit of adding ART in addition to TPE [<xref ref-type="bibr" rid="CR9">9</xref>]. However, in the largest cohort of patients, the Oklahoma Thrombotic Thrombocytopenic Purpura - Hemolytic Uremic Syndrome (TTP-HUS) register, only 1.84 % of 326 patients with TTP had HIV infection and the authors concluded that HIV infection, similar to other inflammatory conditions, could trigger acute episodes of TTP in susceptible patients. Moreover, HIV-induced oncological and infectious disorders could mimic the clinical features of TTP and must be included in the differential diagnosis [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>Our patient&#x02019;s case is remarkable in some aspects. The first and perhaps most interesting is that his acute HIV infection debuted with severe TMA, which to the best of our knowledge has not been previously reported. Negative anti-HIV antibodies with a very high HIV viral load defines acute HIV infection and is characteristically associated with extremely high viremia. Our patient emphasized that sexual risk behaviors were recent events (&#x0003c;1 month), and that bleeding and constitutional symptoms appeared almost immediately upon presumed HIV exposure.</p><p>In this case, TMA was quickly controlled with TPE and prompt ART initiation. Although TPE could have had some role in our patient&#x02019;s recovery, information is not available to support use in TMA. In this particular case, the use of TPE was an extreme action given the severity of the patient&#x02019;s symptoms. In clinical hematology practice it is well recognized that TPE is mainly beneficial in cases where TTP coexists with an immune inhibitor of ADAMTS13, and not in non-immune TMA forms. However, there are several recent reports showing that TPE and other immunological therapies such as rituximab and eculizumab may be useful in cases not necessarily associated with autoimmunity. This effect could be associated to reposition of other coagulation regulatory proteins or modulation of this effect could be associatedwith reposition of other coagulation regulatory proteins or B lymphocytes modulation [<xref ref-type="bibr" rid="CR11">11</xref>].</p></sec><sec id="Sec4" sec-type="conclusion"><title>Conclusions</title><p>We presented an unusual manifestation of acute HIV infection associated with TMA that responded successfully to TPE and prompt start of ART. In patients with TTP or TMA, HIV testing must be mandatory. Furthermore, in patients with known HIV infection, physicians should be aware of the probability of development of thrombotic complications including TTP and TMA.</p></sec></body><back><ack><p>The authors declare that they have no acknowledgements in this manuscript.</p><sec id="FPar1"><title>Authors&#x02019; contributions</title><p>MS, MEB, and PR contributed equally in the treatment of the patient and writing of manuscript. All authors read and approved the final manuscript.</p></sec><sec id="d30e572"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="d30e577"><title>Consent</title><p>Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>NE</given-names></name><name><surname>Pilcher</surname><given-names>CD</given-names></name><name><surname>Busch</surname><given-names>MP</given-names></name><name><surname>Cohen</surname><given-names>MS</given-names></name></person-group><article-title>How can we better identify early HIV infections?</article-title><source>Curr Opin HIV AIDS</source><year>2015</year><volume>10</volume><issue>1</issue><fpage>61</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1097/COH.0000000000000121</pub-id><?supplied-pmid 25389806?><pub-id pub-id-type="pmid">25389806</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hicks</surname><given-names>CB</given-names></name></person-group><article-title>Duke-Unc Acute HIV Infection Consortium</article-title><source>AIDS Res Hum Retroviruses</source><year>2013</year><volume>29</volume><issue>1</issue><fpage>121</fpage><pub-id pub-id-type="doi">10.1089/aid.2012.0064</pub-id><?supplied-pmid 22839749?><pub-id pub-id-type="pmid">22839749</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zucker-Franklin</surname><given-names>D</given-names></name><name><surname>Cao</surname><given-names>YZ</given-names></name></person-group><article-title>Megakaryocytes of human immunodeficiency virus-infected individuals express viral RNA</article-title><source>Proc Natl Acad Sci U S A</source><year>1989</year><volume>86</volume><issue>14</issue><fpage>5595</fpage><pub-id pub-id-type="doi">10.1073/pnas.86.14.5595</pub-id><?supplied-pmid 2748605?><pub-id pub-id-type="pmid">2748605</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Fusco</surname><given-names>G</given-names></name><name><surname>Fusco</surname><given-names>J</given-names></name><name><surname>Balu</surname><given-names>R</given-names></name><name><surname>Gangjee</surname><given-names>S</given-names></name><name><surname>Brennan</surname><given-names>C</given-names></name><etal/></person-group><article-title>HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><issue>Suppl 5</issue><fpage>S267</fpage><pub-id pub-id-type="doi">10.1086/422363</pub-id><?supplied-pmid 15494898?><pub-id pub-id-type="pmid">15494898</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Routy</surname><given-names>JP</given-names></name><name><surname>Beaulieu</surname><given-names>R</given-names></name><name><surname>Monte</surname><given-names>M</given-names></name><name><surname>Saint-Louis</surname><given-names>J</given-names></name><name><surname>Sauvageau</surname><given-names>G</given-names></name><name><surname>Toma</surname><given-names>E</given-names></name></person-group><article-title>Immunologic thrombocytopenia followed by thrombotic thrombocytopenic purpura in two HIV1 patients</article-title><source>Am J Hematol</source><year>1991</year><volume>38</volume><issue>4</issue><fpage>327</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1002/ajh.2830380414</pub-id><?supplied-pmid 1746543?><pub-id pub-id-type="pmid">1746543</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rakhmania</surname><given-names>N</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name><name><surname>Davies</surname><given-names>J</given-names></name><name><surname>Ray</surname><given-names>P</given-names></name></person-group><article-title>Hemorrhagic stroke in an adolescent female with HIV-associated thrombotic thrombocytopenic purpura</article-title><source>AIDS Clin Res</source><year>2014</year><volume>5</volume><issue>6</issue><fpage>311</fpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furlan</surname><given-names>M</given-names></name><name><surname>Robles</surname><given-names>R</given-names></name><name><surname>Galbusera</surname><given-names>M</given-names></name><name><surname>Remuzzi</surname><given-names>G</given-names></name><name><surname>Kyrle</surname><given-names>PA</given-names></name><etal/></person-group><article-title>von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome</article-title><source>N Engl J Med</source><year>1998</year><volume>339</volume><fpage>1578</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1056/NEJM199811263392202</pub-id><?supplied-pmid 9828245?><pub-id pub-id-type="pmid">9828245</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brecher</surname><given-names>ME</given-names></name><name><surname>Hay</surname><given-names>SN</given-names></name><name><surname>Park</surname><given-names>YA</given-names></name></person-group><article-title>Is it HIV TTP or HIV-associated thrombotic microangiopathy?</article-title><source>J Clin Apher.</source><year>2008</year><volume>23</volume><fpage>186</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1002/jca.20176</pub-id><?supplied-pmid 18973113?><pub-id pub-id-type="pmid">18973113</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>RF</given-names></name><name><surname>Scully</surname><given-names>M</given-names></name><name><surname>Cohen</surname><given-names>H</given-names></name><name><surname>Roedling</surname><given-names>S</given-names></name><name><surname>Starke</surname><given-names>R</given-names></name><etal/></person-group><article-title>Thrombotic thrombocytopaenic purpura in HIV-infected patients</article-title><source>Int J STD AIDS.</source><year>2005</year><volume>16</volume><fpage>538</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1258/0956462054679241</pub-id><?supplied-pmid 16105187?><pub-id pub-id-type="pmid">16105187</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamin</surname><given-names>M</given-names></name><name><surname>Terrell</surname><given-names>DR</given-names></name><name><surname>Vesely</surname><given-names>SK</given-names></name><name><surname>Voskuhl</surname><given-names>GW</given-names></name><name><surname>Dezube</surname><given-names>BJ</given-names></name><name><surname>Kremer Hovinga</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><issue>8</issue><fpage>1129</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1086/597471</pub-id><?supplied-pmid 19275493?><pub-id pub-id-type="pmid">19275493</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murugapandian</surname><given-names>S</given-names></name><name><surname>Bijin</surname><given-names>B</given-names></name><name><surname>Mansour</surname><given-names>I</given-names></name><name><surname>Daheshpour</surname><given-names>S</given-names></name><name><surname>Pillai</surname><given-names>BG</given-names></name><name><surname>Thajudeen</surname><given-names>B</given-names></name><etal/></person-group><article-title>Improvement in gemcitabine-induced thrombotic microangiopathy with rituximab in a patient with ovarian cancer: mechanistic considerations</article-title><source>Case Rep Nephrol Dial</source><year>2015</year><volume>5</volume><issue>2</issue><fpage>160</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1159/000435807</pub-id><?supplied-pmid 26266248?><pub-id pub-id-type="pmid">26266248</pub-id></element-citation></ref></ref-list></back></article>